Date: 2014-03-05
Type of information: Collaboration agreement
Compound: DT01 and Dbait-based molecules
Company: DNA Therapeutics (France) Curie Cancer (France)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 5, 2014, Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership. The ongoing collaboration will aim to provide a new class of therapeutic cancer products to patients, including those who are resistant to conventional therapies.The first molecule based on Dbait technology, DT01, is currently being assessed in combination with radiation therapy, in a Phase I clinical trial for approximately 20 patients with cutaneous metastatic chemotherapy-resistant melanoma. DT01 is the result of the partnership between Curie-Cancer and DNA Therapeutics. Dr. Christophe Le Tourneau, head of early-phase clinical trials at the Institut Curie and principal investigator for this trial, has already treated the first patients with this unique class of drugs. Initial results indicate that cancers that are resistant to conventional therapies, including advanced-stage melanoma, can be treated with Dbait technology. DT01 is effective and very well-tolerated in combination with radiation therapy. The full results from Phase I are expected within the next year.
To support this clinical research program, DNA Therapeutics and Curie-Cancer will focus their work on five key areas:
-Further understanding of the Dbait mechanisms of action, to better explain the lack of toxicity of these inhibitors on normal tissue
-Characterize the most responsive tumors as well as the most efficacious combinations with standard therapies to prepare for future clinical trials
-Identify potential resistance mechanisms to Dbait
-Identify predictive biomarkers for responding to Dbait
-Develop second-generation Dbait molecules with improved pharmacokinetic properties.
Financial terms:
Latest news:
